PRE-CLINICAL DEVELOPMENT OF AN IP3K INHIBITOR FOR SOLID CANCER TREATMENT (Q2035314): Difference between revisions

From EU Knowledge Graph
Jump to navigation Jump to search
(‎Changed label, description and/or aliases in da, el, hr, ro, sk, mt, pt, fi, pl, sl, cs, lt, lv, bg, hu, ga, sv, et, nl, fr, de, es, and other parts: Adding translations: da, el, hr, ro, sk, mt, pt, fi, pl, sl, cs, lt, lv, bg, hu, ga, sv, et,)
(‎Changed an Item)
Property / start time
13 December 2016
Timestamp+2016-12-13T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 day
Before0
After0
 
Property / start time: 13 December 2016 / rank
Normal rank
 
Property / beneficiary name (string)
CNR - CONSIGLIO NAZIONALE DELLE RICERCHE
 
Property / beneficiary name (string): CNR - CONSIGLIO NAZIONALE DELLE RICERCHE / rank
Normal rank
 
Property / beneficiary name (string)
MENARINI RICERCHE S.P.A.
 
Property / beneficiary name (string): MENARINI RICERCHE S.P.A. / rank
Normal rank
 
Property / beneficiary
 
Property / beneficiary: Consiglio Nazionale delle Ricerche / rank
Normal rank
 
Property / beneficiary
 
Property / beneficiary: Q282210 / rank
Normal rank
 
Property / budget
1,002,016.42 Euro
Amount1,002,016.42 Euro
UnitEuro
 
Property / budget: 1,002,016.42 Euro / rank
Normal rank
 
Property / EU contribution
500,629.91 Euro
Amount500,629.91 Euro
UnitEuro
 
Property / EU contribution: 500,629.91 Euro / rank
Normal rank
 
Property / co-financing rate
49.96 percent
Amount49.96 percent
Unitpercent
 
Property / co-financing rate: 49.96 percent / rank
Normal rank
 
Property / beneficiary
 
Property / beneficiary: Q282210 / rank
 
Normal rank
Property / beneficiary name (string)
 
MENARINI RICERCHE - S.P.A.
Property / beneficiary name (string): MENARINI RICERCHE - S.P.A. / rank
 
Normal rank
Property / priority axis
 
Property / priority axis: RESEARCH AND INNOVATION / rank
 
Normal rank
Property / thematic objective
 
Property / thematic objective: Research and innovation / rank
 
Normal rank
Property / start time
 
28 December 2017
Timestamp+2017-12-28T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 day
Before0
After0
Property / start time: 28 December 2017 / rank
 
Normal rank
Property / end time
 
24 February 2021
Timestamp+2021-02-24T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 day
Before0
After0
Property / end time: 24 February 2021 / rank
 
Normal rank
Property / budget
 
963,843.12 Euro
Amount963,843.12 Euro
UnitEuro
Property / budget: 963,843.12 Euro / rank
 
Preferred rank
Property / EU contribution
 
471,265.84 Euro
Amount471,265.84 Euro
UnitEuro
Property / EU contribution: 471,265.84 Euro / rank
 
Preferred rank
Property / co-financing rate
 
48.89 percent
Amount48.89 percent
Unitpercent
Property / co-financing rate: 48.89 percent / rank
 
Normal rank
Property / date of last update
 
8 April 2023
Timestamp+2023-04-08T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 day
Before0
After0
Property / date of last update: 8 April 2023 / rank
 
Normal rank

Revision as of 15:20, 8 April 2023

Project Q2035314 in Italy
Language Label Description Also known as
English
PRE-CLINICAL DEVELOPMENT OF AN IP3K INHIBITOR FOR SOLID CANCER TREATMENT
Project Q2035314 in Italy

    Statements

    country
    Italy
    0 references
    EU contribution
    471,265.84 Euro
    0 references
    budget
    963,843.12 Euro
    0 references
    co-financing rate
    48.89 percent
    0 references
    start time
    28 December 2017
    0 references
    end time
    24 February 2021
    0 references
    expected end time
    6 July 2019
    0 references
    beneficiary name (string)
    MENARINI RICERCHE - S.P.A.
    0 references
    beneficiary
    Q282210
    0 references
    programme
    Lazio - ERDF
    0 references
    coordinate location

    41°40'3.11"N, 12°30'17.24"E
    0 references
    summary
    IL PROGETTO SI PROPONE LA CARATTERIZZAZIONE PRECLINICA DEL MEN1611, UN NUOVO INIBITORE DI PI3K CHE HA LA CAPACITà DI INIBIRE IN MODO PREFERENZIALE L?ISOFORMA ALFA, WILD TYPE E MUTATA. VERRANNO STUDIATI I DETERMINANTI MOLECOLARI DELLA SENSIBILITà (Italian)
    0 references
    THE PROJECT IS PROPOSED FOR THE PRE-CLINICAL CHARACTERISATION OF THE MEN1611, A NEW P3K INHIBITOR WHICH HAS THE CAPACITY TO BLOCK, IN A PREFERENTIAL MANNER, THE ALPHA, WILD, AND THE RANGE WHICH HAVE CHANGED. THE MOLECULAR DETERMINANTS OF AWARENESS WILL BE STUDIED. (English)
    0 references
    LE PROJET PROPOSE LA CARACTÉRISATION PRÉCLINIQUE DU MEN1611, UN NOUVEL INHIBITEUR PI3K CAPABLE D’INHIBER PRÉFÉRENTIELLEMENT L’ISOFORME ALPHA, DE TYPE SAUVAGE ET MUTÉ. LES DÉTERMINANTS MOLÉCULAIRES DE LA SENSIBILITÉ SERONT ÉTUDIÉS (French)
    point in time
    16 December 2021
    0 references
    HET PROJECT STELT DE PREKLINISCHE KARAKTERISERING VAN DE MEN1611 VOOR, EEN NIEUWE PI3K-REMMER DIE DE MOGELIJKHEID HEEFT OM BIJ VOORKEUR HET ALFA-ISOFORM, WILDTYPE EN GEMUTEERD TE REMMEN. MOLECULAIRE DETERMINANTEN VAN GEVOELIGHEID ZULLEN WORDEN ONDERZOCHT (Dutch)
    point in time
    23 December 2021
    0 references
    DAS PROJEKT SCHLÄGT DIE PRÄKLINISCHE CHARAKTERISIERUNG DES MEN1611 VOR, EINEM NEUEN PI3K-INHIBITOR, DER DIE FÄHIGKEIT HAT, DIE ALPHA-ISOFORM, WILDE ART UND MUTATION BEVORZUGT ZU HEMMEN. MOLEKULARE DETERMINANTEN DER SENSITIVITÄT WERDEN UNTERSUCHT (German)
    point in time
    24 December 2021
    0 references
    EL PROYECTO PROPONE LA CARACTERIZACIÓN PRECLÍNICA DEL MEN1611, UN NUEVO INHIBIDOR PI3K QUE TIENE LA CAPACIDAD DE INHIBIR PREFERENTEMENTE LA ISOFORMA ALFA, SALVAJE Y MUTADA. SE ESTUDIARÁN LOS DETERMINANTES MOLECULARES DE LA SENSIBILIDAD (Spanish)
    point in time
    25 January 2022
    0 references
    PROJEKTET FORESLÅS MED HENBLIK PÅ DEN PRÆKLINISKE KARAKTERISERING AF MEN1611, EN NY P3K-HÆMMER, SOM HAR KAPACITET TIL AT BLOKERE ALFA, WILD OG DET ÆNDREDE INTERVAL. DE MOLEKYLÆRE DETERMINANTER FOR BEVIDSTHED VIL BLIVE UNDERSØGT. (Danish)
    point in time
    5 July 2022
    0 references
    ΤΟ ΈΡΓΟ ΠΡΟΤΕΊΝΕΤΑΙ ΓΙΑ ΤΟΝ ΠΡΟΚΛΙΝΙΚΌ ΧΑΡΑΚΤΗΡΙΣΜΌ ΤΟΥ MEN1611, ΕΝΌΣ ΝΈΟΥ ΑΝΑΣΤΟΛΈΑ P3K ΠΟΥ ΈΧΕΙ ΤΗΝ ΙΚΑΝΌΤΗΤΑ ΝΑ ΜΠΛΟΚΆΡΕΙ, ΚΑΤΆ ΠΡΟΤΊΜΗΣΗ, ΤΟ ΆΛΦΑ, ΤΟ ΆΓΡΙΟ ΚΑΙ ΤΟ ΕΎΡΟΣ ΠΟΥ ΈΧΕΙ ΑΛΛΆΞΕΙ. ΘΑ ΜΕΛΕΤΗΘΟΎΝ ΟΙ ΜΟΡΙΑΚΟΊ ΚΑΘΟΡΙΣΤΙΚΟΊ ΠΑΡΆΓΟΝΤΕΣ ΤΗΣ ΕΥΑΙΣΘΗΤΟΠΟΊΗΣΗΣ. (Greek)
    point in time
    5 July 2022
    0 references
    PROJEKT JE PREDLOŽEN ZA PRETKLINIČKU KARAKTERIZACIJU MEN1611, NOVOG P3K INHIBITORA KOJI MOŽE NA POVLAŠTENI NAČIN BLOKIRATI ALFA, DIVLJE I RASPON KOJI SU SE PROMIJENILI. PROUČAVAT ĆE SE MOLEKULARNE ODREDNICE SVIJESTI. (Croatian)
    point in time
    5 July 2022
    0 references
    PROIECTUL ESTE PROPUS PENTRU CARACTERIZAREA PRECLINICĂ A MEN1611, UN NOU INHIBITOR P3K CARE ARE CAPACITATEA DE A BLOCA, ÎN MOD PREFERENȚIAL, ALFA, SĂLBATIC ȘI GAMA CARE S-A SCHIMBAT. FACTORII MOLECULARI DETERMINANȚI AI CONȘTIENTIZĂRII VOR FI STUDIAȚI. (Romanian)
    point in time
    5 July 2022
    0 references
    PROJEKT JE NAVRHNUTÝ PRE PREDKLINICKÚ CHARAKTERIZÁCIU MEN1611, NOVÉHO INHIBÍTORA P3K, KTORÝ MÁ SCHOPNOSŤ PREDNOSTNE BLOKOVAŤ ALFA, DIVOKÝ A ROZSAH, KTORÝ SA ZMENIL. MOLEKULÁRNE DETERMINANTY POVEDOMIA SA BUDÚ SKÚMAŤ. (Slovak)
    point in time
    5 July 2022
    0 references
    IL-PROĠETT HUWA PROPOST GĦALL-KARATTERIZZAZZJONI PREKLINIKA TAL-MEN1611, INIBITUR P3K ĠDID LI GĦANDU L-KAPAĊITÀ LI JIMBLOKKA, B’MOD PREFERENZJALI, L-ALFA, IS-SELVAĠĠ, U L-FIRXA LI NBIDLU. ID-DETERMINANTI MOLEKULARI TAL-GĦARFIEN SE JIĠU STUDJATI. (Maltese)
    point in time
    5 July 2022
    0 references
    O PROJETO É PROPOSTO PARA A CARACTERIZAÇÃO PRÉ-CLÍNICA DO MEN1611, UM NOVO INIBIDOR P3K QUE TEM A CAPACIDADE DE BLOQUEAR, DE FORMA PREFERENCIAL, O ALFA, SELVAGEM E O INTERVALO QUE MUDARAM. OS DETERMINANTES MOLECULARES DA CONSCIÊNCIA SERÃO ESTUDADOS. (Portuguese)
    point in time
    5 July 2022
    0 references
    HANKKEELLE EHDOTETAAN MEN1611:N ESIKLIINISTÄ LUONNEHDINTAA, JOKA ON UUSI P3K-INHIBIITTORI, JOKA PYSTYY ENSISIJAISESTI ESTÄMÄÄN ALFAN, VILLIN JA MUUTTUNEEN ALUEEN. TIETOISUUDEN MOLEKULAARISIA TAUSTATEKIJÖITÄ TUTKITAAN. (Finnish)
    point in time
    5 July 2022
    0 references
    PROJEKT PROPONUJE SIĘ DLA PRZEDKLINICZNEJ CHARAKTERYSTYKI MEN1611, NOWEGO INHIBITORA P3K, KTÓRY MA ZDOLNOŚĆ BLOKOWANIA, W SPOSÓB UPRZYWILEJOWANY, ALFA, DZIKIEGO I ZMIENIONEGO ZAKRESU. MOLEKULARNE WYZNACZNIKI ŚWIADOMOŚCI ZOSTANĄ ZBADANE. (Polish)
    point in time
    5 July 2022
    0 references
    PROJEKT JE PREDLAGAN ZA PREDKLINIČNO KARAKTERIZACIJO MEN1611, NOVEGA ZAVIRALCA P3K, KI IMA SPOSOBNOST, DA PREDNOSTNO BLOKIRA ALFA, DIVJINO IN OBSEG, KI SO SE SPREMENILI. PROUČILI BOMO MOLEKULARNE DETERMINANTE ZAVEDANJA. (Slovenian)
    point in time
    5 July 2022
    0 references
    PROJEKT JE NAVRŽEN PRO PŘEDKLINICKÉ CHARAKTERIZACI MEN1611, NOVÉHO INHIBITORU P3K, KTERÝ MÁ SCHOPNOST PREFERENČNÍM ZPŮSOBEM BLOKOVAT ALFA, DIVOCE A ROZSAH, KTERÝ SE ZMĚNIL. MOLEKULÁRNÍ DETERMINANTY POVĚDOMÍ BUDOU STUDOVÁNY. (Czech)
    point in time
    5 July 2022
    0 references
    PROJEKTAS SIŪLOMAS DĖL NAUJO P3K INHIBITORIAUS MEN1611, KURIS GALI PIRMUMO TVARKA BLOKUOTI ALFA, LAUKINĮ IR PASIKEITUSĮ DIAPAZONĄ, IKIKLINIKINIO APIBŪDINIMO. BUS TIRIAMI MOLEKULINIAI SĄMONINGUMO VEIKSNIAI. (Lithuanian)
    point in time
    5 July 2022
    0 references
    PROJEKTS IR IEROSINĀTS MEN1611 — JAUNA P3K INHIBITORA — PREKLĪNISKAJAI RAKSTUROŠANAI, KAS SPĒJ PREFERENCIĀLĀ VEIDĀ BLOĶĒT ALFA, SAVVAĻĀ UN AMPLITŪDĀ, KAS IR MAINĪJUSIES. TIKS PĒTĪTI IZPRATNES MOLEKULĀRIE FAKTORI. (Latvian)
    point in time
    5 July 2022
    0 references
    ПРОЕКТЪТ Е ПРЕДЛОЖЕН ЗА ПРЕДКЛИНИЧНА ХАРАКТЕРИСТИКА НА MEN1611, НОВ P3K ИНХИБИТОР, КОЙТО ИМА СПОСОБНОСТТА ДА БЛОКИРА, ПО ПРЕФЕРЕНЦИАЛЕН НАЧИН, АЛФА, ДИВА ПРИРОДА И ПРОМЕНЕНАТА ГАМА. ЩЕ БЪДАТ ПРОУЧЕНИ МОЛЕКУЛЯРНИТЕ ДЕТЕРМИНАНТИ НА ОСЪЗНАВАНЕТО. (Bulgarian)
    point in time
    5 July 2022
    0 references
    A PROJEKT A MEN1611 – EGY ÚJ P3K-GÁTLÓ – PREKLINIKAI JELLEMZÉSÉRE VONATKOZIK, AMELY LEHETŐVÉ TESZI, HOGY PREFERENCIÁLIS MÓDON BLOKKOLJA AZ ALFA, A VAD ÉS A MEGVÁLTOZOTT TARTOMÁNYT. A TUDATOSSÁG MOLEKULÁRIS MEGHATÁROZÓIT TANULMÁNYOZZÁK. (Hungarian)
    point in time
    5 July 2022
    0 references
    TÁ AN TIONSCADAL BEARTAITHE DO THRÉITHRIÚ RÉAMHCHLINICIÚIL AN MEN1611, COSCAIRE P3K NUA A BHFUIL SÉ DE CHUMAS AIGE AN ALFA, AN FIÁIN AGUS AN RAON ATÁ ATHRAITHE A BHLOCÁIL AR BHEALACH FABHRACH. DÉANFAR STAIDÉAR AR NA DEITÉARMANAINT MHÓILÍNEACHA FEASACHTA. (Irish)
    point in time
    5 July 2022
    0 references
    PROJEKTET FÖRESLÅS FÖR PREKLINISK KARAKTERISERING AV MEN1611, EN NY P3K-HÄMMARE SOM HAR KAPACITET ATT PÅ ETT FÖRMÅNLIGT SÄTT BLOCKERA ALFA, WILD OCH DET OMRÅDE SOM HAR FÖRÄNDRATS. DE MOLEKYLÄRA BESTÄMNINGSFAKTORERNA FÖR MEDVETENHET KOMMER ATT STUDERAS. (Swedish)
    point in time
    5 July 2022
    0 references
    PROJEKT ON KAVANDATUD UUE P3K INHIBIITORI MEN1611 PREKLIINILISEKS ISELOOMUSTAMISEKS, MIS SUUDAB EELISTATULT BLOKEERIDA MUUTUNUD ALFA-, METSIKU JA VAHEMIKU. UURITAKSE TEADLIKKUSE MOLEKULAARSEID DETERMINANTE. (Estonian)
    point in time
    5 July 2022
    0 references
    location (string)
    POMEZIA
    0 references
    date of last update
    8 April 2023
    0 references

    Identifiers

    Italian Unique Project Code
    F57H18000070007
    0 references
     
    Retrieved from "https://linkedopendata.eu/w/index.php?title=Item:Q2035314&oldid=33786723"